<DOC>
	<DOCNO>NCT02242318</DOCNO>
	<brief_summary>The primary aim trial compare telmisartan 80 mg valsartan 160 mg lower diastolic blood pressure patient miss dose medication , measure ABPM ( change baseline mean DBP 24 hour ) , compare telmisartan 80 mg valsartan 160 mg lower DBP last six hour dose interval end 6 8-week treatment period , measure ABPM ( change baseline )</brief_summary>
	<brief_title>Study Evaluate Efficacy Micardis® ( Telmisartan ) Valsartan Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Mildtomoderate hypertension define mean seat diastolic blood pressure ≥ 95 mmHg ≤ 109 mmHg , measure manual cuff sphygmomanometer , Visit 2 2 . 24hour mean DBP ≥ 85 mmHg Visit 3 measure ABPM 3 . Age 18 year old 4 . Ability stop current antihypertensive therapy without risk patient ( investigator 's discretion ) 5 . Patient 's write informed consent accordance Good Clinical Practice ( GCP ) local legislation 1 . Premenopausal woman ( last menstruation ≤ 1 year prior start runin period ) 1. surgically sterile , 2. nursing , 3. childbearing potential NOT practise acceptable method birth control , NOT plan continue practise acceptable method throughout study . Acceptable method birth control include oral , implantable injectable contraceptive Intra Uterine Devices ( IUD ) 2 . Known suspected secondary hypertension 3 . Mean sit SBP ≥180 mmHg mean sit DBP ≥110 mmHg visit placebo runin period 4 . Hepatic and/or renal dysfunction define follow laboratory parameter : 1 . Serum GlutamatePyruvateTransaminase ( Alanine Aminotransferase ) ( SGPT ( ALT ) ) Serum GlutamateOxaloacetateTransaminase ( Aspartate Aminotransferase ) ( SGOT ( AST ) ) &gt; 2 time upper limit normal range , 2 . Serum creatinine &gt; 2.3 mg/dL ( &gt; 203 μmol/l ) 5 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , patient postrenal transplant one kidney 6 . Clinically relevant sodium depletion , hypokalaemia hyperkalaemia 7 . Uncorrected volume depletion 8 . Primary aldosteronism 9 . Hereditary fructose intolerance 10 . Biliary obstructive disorder 11 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonists 12 . History drug alcohol dependency within six month prior start runin period 13 . Concomitant administration medication know affect blood pressure , except medication allow protocol 14 . Any investigational therapy within one month signing informed consent form 15 . Congestive heart failure ( New York Heart Association ( NYHA ) functional class Congestive Heart Failure ( CHF IIIIV ) ) 16 . Unstable angina within past three month prior start runin period 17 . Stroke within past six month prior start runin period 18 . Myocardial infarction cardiac surgery within past three month prior start runin period 19 . Percutaneous Transluminal Coronary Angioplasty ( PTCA ) within past three month prior start runin period 20 . Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator 21 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve 22 . Patients insulindependent diabetes mellitus whose diabetes stable control least past three month define HbA1C ≥ 10 % 23 . Night shift worker routinely sleep daytime whose work hour include midnight 4:00 Ante Meridiem ( AM ) 24 . Known hypersensitivity component formulation 25 . Any clinical condition , opinion investigator would allow safe completion protocol safe administration trial medication 26 . Inability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>